SPONSOR

Sun Yat-sen University

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 1, Phase 2, Phase 3

Conditions studied: Nasopharyngeal Cancinoma (NPC)Transarterial Chemoembolization Systemic Therapy Unresectable Hepatocellular Carcinoma Classical Hodgkin Lymphoma Ewing Sarcoma Mantle Cell Lymphoma (MCL)Nasopharyngeal Carcinoma De-escaltion Therapy Hepatocellular Carcinoma

Sun Yat-sen University is a clinical research sponsor with 50 registered studies on ClinicalTrials.gov, of which 50 are actively recruiting participants. Research covers conditions including Nasopharyngeal Cancinoma (NPC), Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma.

The trial portfolio spans Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Sun Yat-sen University

How many clinical trials has Sun Yat-sen University sponsored?

ClinicalMetric currently tracks 50 clinical trials sponsored by Sun Yat-sen University, of which 50 are actively recruiting participants. These trials cover conditions including Nasopharyngeal Cancinoma (NPC), Transarterial Chemoembolization, Systemic Therapy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Sun Yat-sen University research focus on?

Sun Yat-sen University clinical trials span Nasopharyngeal Cancinoma (NPC), Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Sun Yat-sen University clinical trial?

To participate in a Sun Yat-sen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sun Yat-sen University trials with current recruitment status updated daily.

Sun Yat-sen University

Frequently Asked Questions — Sun Yat-sen University

Clinical Trials by Sun Yat-sen University

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis

Afterload Mismatch Predictive modLE for Transcatheter Edge-to-Edge Repair (AMPLE-TEER)

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Arsenous Acid for Refractory Triple-Negative Breast Cancer

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Epstein-Barr Virus and Cancer Risks

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy

Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Safety and Efficacy of Two-step Radical Prostatectomy

Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma

Lymphadenectomy in Early Ovarian Cancer

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy

TACE Combined Surgery for the Resectable Huge HCC

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Evaluation of COVID-19 Immune Barrier and Reinfection Risk

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites